

JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,
Sector-18, Gurugram -122015, Haryana (India)

Sakhi A CSR Initiative

September 02, 2025

The Department of Corporate Services- Listing	The Department of Corporate Services- Listing
BSE Ltd,	National Stock Exchange of India Ltd
Phiroze Jeejeebhoy Towers,	Exchange Plaza, C-1, Block G,
Dalal Street	Bandra Kurla Complex,
Mumbai-400 001	Bandra (E) Mumbai – 400 051
Scrip Code: 507789	Symbol: JAGSNPHARM

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

In terms of the requirements of Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has issued letters to those Shareholder's whose e-mail addresses are not registered with the Company/Depository Participants, providing the web-link along with the path to access the Annual Report 2024-25 including Notice of AGM of the Company on the Company's website. The specimen copy of letter sent to shareholders is enclosed herewith.

You are requested to kindly take the same on record.

Thanking you,

For Jagsonpal Pharmaceuticals Limited

Pratham Rawal Company Secretary & Compliance Officer

Encl.: A/a

Regd. Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 (India) **Mumbai Office:** 13-14, Unit 3B, Phoenix Paragon Plaza, Kurla West, Mumbai, Maharashtra- 400070



JAGSONPAL PHARMACEUTICALS LIMITED

Registered Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi- 110020 Corp. Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Sector -18, Gurugram – 122015, Haryana, (India) CIN: L74899DL1978PLC009181

Phone: +91 124 4406710, E-mail: cs@jagsonpal.com, Website: www.jagsonpal.com

me :-	
dress 1:-	
dress 2:-	
dress 3:-	
y :-	
te:-	
code :-	
b:-	
ar Shareholder(s),	
e: Web-link and Path for accessing Annual Report for the Financial Year 2024-25	
io No	

We are pleased to inform you that the 46th Annual General Meeting (AGM) of Jagsonpal Pharmaceuticals Limited (the Company) is scheduled to be held on Wednesday, 24th September, 2025 at 03:30 P.M. (IST) through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) to transact the business as set out in the Notice dated 8th August, 2025 convening the AGM, in compliance with the various circulars issued by MCA and SEBI from time to time.

The Notice of the 46th AGM along with the Annual Report for the financial year 2024-25 is being sent by electronic mode to Members whose e-mail ids are registered with the Company / Registrar & Share Transfer Agent (RTA) or the Depository Participants (DPs).

In terms of Regulation 36(1) (b) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, in the absence of your email id registered with the RTA/Depository Participant, this letter is being sent to you to provide the web-link along with the path to access the Annual Report including Notice of the AGM of the Company, which is given below:

Web Link: https://www.jagsonpal.com/annual-report/

Path: https://www.jagsonpal.com/annual-report/ > Jagsonpal Pharmaceuticals Limited > Investor Relation > Annual Report 2025

Detailed information with respect to procedure for e-voting and participation at the AGM, speaker registration, dividend, etc. is contained in the Notice convening the AGM. For any further information in this regard, please reach out to the Company's Registrar and Share Transfer Agent- MCS Share Transfers Agent Limited at admin@mcsregistrars.com or to the Company at cs@jagsonpal.com

For Jagsonpal Pharmaceuticals Limited

Sd/-Pratham Rawal Company Secretary & Compliance officer